Advances in Antibody-drug Conjugates for Non-small Cell Lung Cancer
after Resistance to First-line Therapy.
10.3779/j.issn.1009-3419.2025.101.14
- Author:
Honglin LI
1
;
Yawan JING
2
;
Jiayi SUN
1
;
Jing XU
3
;
Yalun LI
1
Author Information
1. Department of Pulmonary and Critical Care Medicine, State Key Laboratory of Respiratory Health and Multimorbidity, Institute of Respiratory Health and Multimorbidity, Institute of Respiratory Health, Frontiers Science Center for Disease-related Molecular Net work, Precision Medicine Center/Precision Medicine Key Laboratory of Sichuan Province, West China Hospital, Sichuan University, Chengdu 610041, China.
2. Department of Gerontology and Geriatrics, Tibet Autonomous Region People's Hospital, Lhasa 850000, China.
3. Integrated Care Management center, West China Hospital, Sichuan University, Chengdu 610041, China.
- Publication Type:English Abstract
- Keywords:
Antibody-drug conjugate;
Coping strategies;
Drug resistance;
Lung neoplasms
- MeSH:
Humans;
Carcinoma, Non-Small-Cell Lung/drug therapy*;
Immunoconjugates/chemistry*;
Lung Neoplasms/drug therapy*;
Drug Resistance, Neoplasm/drug effects*;
Antineoplastic Agents/chemistry*
- From:
Chinese Journal of Lung Cancer
2025;28(9):710-720
- CountryChina
- Language:Chinese
-
Abstract:
Antibody-drug conjugate (ADC), a novel class of antineoplastic agents, combines tumor-specific targeting with potent cytotoxic activity. In recent years, ADC has achieved notable advances in the treatment of non-small cell lung cancer (NSCLC), particularly within therapeutic sequencing after failure of first-line therapy or the emergence of resistance. This paper will systematically review the efficacy and safety evidence of representative ADC in NSCLC, and further to discuss progress and challenges in ADC structural optimization, toxicity management, biomarker identification, and combination strategies, aiming to provide a comprehensive theoretical foundation and practical reference for clinical practice and future research.
.
